About Overview Management Team Board of Directors Partnering Contact Programs Pipeline A4250 A3384 Elobixibat Nonalcoholic Steatohepatitis (NASH) Science Bile Acids and IBAT Inhibition Publications Links Patients & Families Progressive Familial Intrahepatic Cholestasis (PFIC) Nonalcoholic Steatohepatitis (NASH) Chronic (Idiopathic) Constipation Bile Acid Malabsorption (BAM) Clinical Trials Expanded Use Media & Investors Careers Current Openings Search Relentlessly Focused on Liver Disease Exploiting the power of bile acid modulation to pursue new potential treatment options to improve the lives of people living with liver disease. Discover More Targeted Expertise. Brighter Outcomes. There are currently no approved drug therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Our goal is to change that. LEARN MORE Backed by Deep Knowledge of IBAT Inhibition Dedicated to the development of novel bile acid modulators to relieve the pain and suffering of people living with orphan liver diseases. Read Our Science Better Pediatric Liver Solutions are in Development Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology. View Pipeline Albireo's A4250 is a potent and selective IBAT inhibitor We are developing A4250 initially to treat patients with PFIC, a rare genetic liver disease. View A4250's MOA A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder. Download Now Recent News, Events & Presentations View all Press Releases View all Events & Presentations © 2018 Albireo Pharma, Inc. Contact | Terms of Use | Privacy Policy